Immutep reports Phase II neoadjuvant efti success in sarcoma via 6-K

Rhea-AI Filing Summary

Immutep Limited furnished a Form 6-K noting that the EFTISARC-NEO Phase II trial evaluating neoadjuvant efti in soft tissue sarcoma met its primary endpoint, with data presented at the ESMO Congress 2025.

The update is provided via Exhibit 99.1. Additional clinical details would be contained in the exhibit presentation materials.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date as October 20, 2025

Commission File Number 001-35428

IMMUTEP LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

Level 32, Australia Square

264 George Street, Sydney

NSW 2000, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐   No ☒

If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 20, 2025

IMMUTEP LIMITED
By:		/s/ Marc Voigt
Name:		Marc Voigt
Title:		Chief Executive Officer

FAQ

What did IMMP report in its Form 6-K?

Immutep reported that the EFTISARC-NEO Phase II trial met its primary endpoint and that data were presented at ESMO Congress 2025.

Which trial is referenced by IMMP?

The EFTISARC-NEO Phase II trial evaluating neoadjuvant efti in soft tissue sarcoma.

What milestone was achieved in the trial?

The trial met its primary endpoint, as stated in Exhibit 99.1.

Where were the data presented for IMMP’s study?

At the ESMO Congress 2025.

Where can investors find more details?

See Exhibit 99.1 titled “Primary Endpoint Met in EFTISARC-NEO Phase II…” included with the Form 6-K.